CoChat

GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis

Open access
Rezaei, Shahla, Tabrizi, Reza, Nowrouzi-Sohrabi, Peyman, Jalali, Mohammad, Atkin, Stephen L., Al-Rasadi, Khalid, Jamialahmadi, Tannaz, Sahebkar, Amirhossein · 2021 · Canadian Journal of Gastroenterology and Hepatology

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Aims. This meta‐analysis of randomized placebo‐controlled clinical trials assessed the effect of glucose‐like peptide‐1‐receptor agonists (GLP‐1RA) on the lipid profile and liver enzymes in patients with nonalcoholic fatty liver disease (NAFLD). Materials and Methods. Randomized placebo‐controlled trials investigating GLP‐1RA on the lipid profile and liver enzymes in patients with NAFLD were searched in PubMed‐Medline, Scopus, Web of Science, and Google Scholar databases (from inception to January 2020). A random‐effects model and a generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted. Weighted random‐effects meta‐regression was performed on potential confounders on lipid profile and liver enzyme concentrations. Results. 12 studies were identified (12 GLP‐1RA arms; 677 subjects) that showed treatment with GLP‐1RA reduced alanine transaminase (ALT) concentrations (WMD = −10.14, 95%CI = [−15.84, −0.44], P < 0.001), gamma‐glutamyl transferase (GGT) (WMD = −11.53, 95%CI = [−15.21,−7.85], P < 0.001), and alaline phosphatase (ALP) (WMD = −8.29, 95%CI = [−11.34, −5.24], P < 0.001). Aspartate aminotransferase (AST) (WMD = −2.95, 95% CI = [−7.26, 1.37], P = 0.18) was unchanged. GLP‐1 therapy did not alter triglycerides (TC) (WMD = −7.07, 95%CI = [−17.51, 3.37], P = 0.18), total cholesterol (TC) (WMD = −1.17 (−5.25, 2.91), P = 0.57), high‐density lipoprotein (HDL‐C) (WMD = 0.97, 95%CI = [−1.63, 3.58], P = 0.46), or low‐density lipoprotein (LDL‐C) (WMD = −1.67, 95%CI = [−10.08, 6.74], P = 0.69) in comparison with controls. Conclusion. The results of this meta‐analysis suggest that GLP‐1RA treatment significantly reduces liver enzymes in patients with NAFLD, but the lipid profile is unaffected.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2021/8936865

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flowchart of study selection method.
Figure 1 Flowchart of study selection method.CC BY · PubMed Central
Figure 2 Details of quality assessment of the included papers.
Figure 2 Details of quality assessment of the included papers.CC BY · PubMed Central
Figure 3 Meta-analysis of weighted mean differences estimates for lipid profiles including (a) total cholesterol, (b) triglycerides, (c) HDL-cholesterol, and (d) LDL-cholesterol in intervention and placebo groups (CI = 95%).
Figure 3 Meta-analysis of weighted mean differences estimates for lipid profiles including (a) total cholesterol, (b) triglycerides, (c) HDL-cholesterol, and (d) LDL-cholesterol in intervention and placebo groups (CI = 95%).CC BY · PubMed Central
Figure 4 Meta-analysis of weighted mean differences estimates for liver enzymes including (a) aspartate aminotransferase, (b) alanine aminotransferase, (c) gamma-glutamyltransferase, and (d) alkaline phosphatase in intervention and placebo groups (CI = 95%).
Figure 4 Meta-analysis of weighted mean differences estimates for liver enzymes including (a) aspartate aminotransferase, (b) alanine aminotransferase, (c) gamma-glutamyltransferase, and (d) alkaline phosphatase in intervention and placebo groups (CI = 95%).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 2

  1. WangD. J. J. M. U. Effect of exenatide combined with metformin therapy on insulin resistance liver function and inflammatory response in patients with type 2 diabetes mellitus combined with NAFLD Journal of Hainan Medical University 2017 23 no. 18 44–47.
  2. Khoo J., 2019, Comparing effects of liraglutide-induced weight loss versus lifestyle modification on liver fat content and plasma acylcarnitine levels in obese adults with nonalcoholic fatty liver disease, Obesity Facts, 12

Cited by

Metadata

Authors
Rezaei, S., Tabrizi, R., Nowrouzi-Sohrabi, P., Jalali, M., Atkin, S. L., Al-Rasadi, K., Jamialahmadi, T., & Sahebkar, A.
Affiliations
  • Shiraz University (IR)
  • Fasa University of Medical Sciences (IR)
  • Shiraz University of Medical Sciences (IR)
  • Weill Cornell Medical College in Qatar (QA)
  • Mashhad University of Medical Sciences (IR)
Corresponding author
Sahebkar, Amirhossein
Venue
Canadian Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
2021-01
Volume
2021
Issue
1
Pages
8936865-8936865
ISSN
  • 2291-2789 (ISSN-L)
  • 2291-2797
OpenAlex
W3211702740
Cited by
65
References
43
Citations by year
2026: 12 · 2025: 16 · 2024: 17 · 2023: 9 · 2022: 11
FWCI
1.42
Type
journal article
Language
en
Open access
Locations
  • Canadian Journal of Gastroenterology and Hepatology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
GLP-1 receptor agonists, non-alcoholic fatty liver disease, lipid profile, liver enzymes, alanine aminotransferase, gamma-glutamyl transferase, aspartate aminotransferase, alkaline phosphatase, triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, LDL particle number, dyslipidemia
MeSH terms
Glucagon-Like Peptide-1 Receptor, Humans, Lipids, Triglycerides, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.